Hidradenitis Suppurativa Epidemiology Forecast 2025-2034

A 2021 systematic review and meta-regression analysis published in JAMA Dermatology estimated the prevalence of hidradenitis suppurativa to be between less than 1% and 4%. The condition typically starts between puberty and 40 years, with the highest incidence occurring between ages 21 and 29.

Hidradenitis Suppurativa Epidemiology Forecast Report Coverage

The “Hidradenitis Suppurativa Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hidradenitis suppurativa. It projects the future incidence and prevalence rates of hidradenitis suppurativa across various populations. The study covers age and type as major determinants of the hidradenitis suppurativa-affected population. The report highlights patterns in the prevalence of hidradenitis suppurativa over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hidradenitis suppurativa in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hidradenitis Suppurativa: Disease Overview

Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful, swollen lumps, abscesses, and tunnels under the skin. It is typically observed in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. The condition occurs when hair follicles and sweat glands become blocked and inflamed. Hidradenitis suppurativa often starts after puberty and can worsen over time. Symptoms include recurring abscesses, draining tunnels, and scarring, among others.

Hidradenitis Suppurativa: Treatment Overview

For the treatment of hidradenitis suppurativa, medications such as antibiotics (topical clindamycin or oral tetracycline), are generally used to reduce bacterial growth and inflammation. Corticosteroids, both topical and injectable, help in managing pain and swelling during flare-ups. Biologic medications, including TNF-alpha inhibitors like adalimumab (Humira), are often prescribed for moderate to severe cases. Immunosuppressive drugs (methotrexate or cyclosporine) are sometimes used when the patient fails to respond to other treatments.

Epidemiology

The hidradenitis suppurativa epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for hidradenitis suppurativa by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hidradenitis suppurativa and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The prevalence of hidradenitis suppurativa is estimated to be between less than 1% and 4%, as per a 2021 systematic review and meta-regression analysis published in JAMA Dermatology. However, these numbers are likely underestimated due to underreporting and misdiagnosis.
• Hidradenitis suppurativa patients have twice the risk of cardiovascular disease death compared to those without the condition and 1.5 times the risk compared to those with psoriasis.
• About 33% to 40% of people with hidradenitis suppurativa reported having a first-degree relative with the condition, suggesting an autosomal dominant inheritance, according to a study published in Clinics in Dermatology (2023).
• An article published in the British Journal of Dermatology (2021) revealed that in North America and Europe, hidradenitis suppurativa is more common in females, with a female-to-male ratio of about 3:1. However, in South Korea, the condition is more prevalent in males, with a ratio of 1:2.

Country-Wise Hidradenitis Suppurativa Epidemiology

The hidradenitis suppurativa epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hidradenitis suppurativa varies significantly between countries due to differences in genetic factors, healthcare access, lifestyle patterns, environmental influences, diagnostic practices, and cultural perceptions of the condition. A 2020 study published in Archives of Dermatological Research examined 20,112 people in 343 German companies between 2014 and 2017 for hidradenitis suppurativa, finding a point prevalence of 0.3%.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hidradenitis suppurativa based on several factors.
• The Hidradenitis Suppurativa Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of hidradenitis suppurativa are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hidradenitis suppurativa epidemiology in the 8 major markets?
• What will be the total number of patients with hidradenitis suppurativa across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hidradenitis suppurativa in the 8 major markets in the historical period?
• Which country will have the highest number of hidradenitis suppurativa patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hidradenitis suppurativa during the forecast period of 2025-2034?
• What are the currently available treatments for hidradenitis suppurativa?
• What are the disease risks, signs, symptoms, and unmet needs of hidradenitis suppurativa?

This product will be delivered within 3-5 business days.